Addressing gaps in clinically useful evidence on drug-drug interactions

潜在的药物-药物相互作用（pddi）是药物不良反应的重要因果关系

Potential drug-drug interactions (PDDIs) represent a significant causality for adverse drug events. Unfortunately, current resources for providers are incomplete and inaccurate. We propose a new PDDI knowledge representation paradigm that we hypothesize will yield more clinically relevant evidence than is currently possible. Starting from our extensive body of preliminary work, we will build a framework that implements the new paradigm using statins and psychotropics (antidepressants and antipsychotics). We expect that the framework will be generalizable to PDDIs involving other drugs, including those predicted using methods from pharmacology and bioinformatics. We will advance three research aims while building the exemplar framework. The first research aim is to derive a new meta-data standard for representing PDDI knowledge that satisfies the information needs of pharmacist working in different care settings. An information needs inquiry will result in clinical scenarios that will then inform, and later validate, the new standard. We will design the standard so that it reflects the best thinking of Semantic Web community and will have a high likelihood of widespread adoption. We will then combine the new standard with semantic annotation and best practices for publishing Linked Data to create a Semantic Web knowledge base of statin and psychotropic PDDIs. The second research aim is to compare PDDI evidence on the Semantic Web with existing PDDI knowledge resources for completeness, accuracy and currency. We will validate a mechanism for linking statin and psychotropic PDDI assertions to relevant evidence on the Semantic Web. Because pharmacogenomics can impact many PDDIs, we will also link to an interoperable representation of this evidence. Two pharmacists will then compare the coverage and quality of the PDDI evidence on the Semantic Web with three existing resources using a new PDDI evidence scoring tool. The third research aim is to investigate a process for filling in gaps in clinically useful PDDI knowledge that cannot be filled with available evidence. We will utilize a consensus-based approach to select high priority PDDIs and evaluate their clinical relevance by retrospective cohort studies. We will extend the Linked Data PDDI knowledge base with the results of these studies, and make the knowledge base publicly available via a pilot web portal. The proposed work will contribute to public health by making more effective use of PDDI evidence, filling in important gaps in drug safety knowledge, and spurring innovations in drug information retrieval.